CSPC PHARMA(01093.HK): Antibody-Drug Conjugate SYS6051 Approved for Clinical Trials for Advanced Solid Tumors

NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) released a voluntary announcement on April 15, 2026, disclosing that SYS6051, developed by the Group, has obtained clinical trial approval from the National Medical Products Administration (NMPA) of China.
The product is a human tissue factor (TF)-targeted antibody-drug conjugate (ADC). It binds to tissue factor expressed on the surface of tumor cells, enters the cells via endocytosis, and releases cytotoxic payloads to kill cancer cells. Filed as a Class 1 therapeutic biological product, the approved indication for this trial is advanced solid tumors.
Preclinical studies have shown that the product demonstrates promising anti-tumor activity across multiple cancer types, and is expected to exhibit favorable therapeutic efficacy in subsequent clinical trials.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.